Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06240871 · ClinicalTrials.gov registry record
Contrast Enhanced PA Pressure Measurements
A clinical trial, sponsored by Northwestern University.
- Completed
- Registry status
- 90
- Enrollment target
NCT06240871: Completed study, sponsored by Northwestern University.
NCT06240871 is a clinical trial that has completed, run by Northwestern University. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06240871 has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
Pulmonary hypertension (PH) is an abnormal increase of the pressure inside the lung circulation. This condition can be caused by many different diseases. If PH persists for a long period of time, irreversible damage to the lung circulation and to the heart may ensue. A definitive diagnosis of PH requires direct measurement of the pressure within the lung circulation with a procedure called right heart catheterization (RHC). While overall safe, RHC is an invasive procedure and is associated with a small risk of complications (\~1.1%) and, very rarely, death (0.055%), even when performed in experienced laboratories. Therefore, alternative diagnostic approaches are often employed such as an ultrasound technique called Doppler echocardiography which is non-invasive, relatively inexpensive and widely available technique. It is suitable not only as a screening tool but also for serial monitoring of disease progression in PH. However, the accuracy of Doppler echocardiography in measuring pressure in the lung circulation appears to be modest in patients with suspected PH. To improve the performance of Doppler echocardiography it is common practice to inject a small amount of agitated saline or an echocardiographic contrast medium (usually composed of microbubbles of fat containing a minuscule amount of a gas) into a vein. However, the accuracy of using agitated saline or a contrast agent in the measurement of pressures inside the lung circulation has not been established. The proposed study will assess the accuracy of Doppler echocardiographic measurements of pressures in the pulmonary circulation by simultaneously comparing the pressures collected during a RHC. The investigators will enroll 100 consecutive patients undergoing RHC in the Catheterization Laboratory of Northwestern Memorial Hospital. The investigators will measure pulmonary pressures by RHC and by Doppler echocardiography at baseline and following the injection of agitated saline as well as Optison®, an FDA-a
Primary Outcome
Doppler echo measurements: Estimated pulmonary artery (PA) systolic pressure without any contrast (units = mmHg) Estimated PA systolic pressure with agitated saline contrast (units = mmHg) Estimated PA systolic pressure with echocardiographic contrast (units = mmHg) Right heart catheterization (RHC) measurements: Invasively measured PA systolic pressure (units = mmHg)
Interventions
- OTHER Pulmonary artery pressure measurements
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-09 |
What the finished NCT06240871 record still lists
NCT06240871 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Pulmonary artery pressure measurements is the first listed.
NCT06240871 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06240871 about?
NCT06240871 is a clinical study titled "Contrast Enhanced PA Pressure Measurements". Pulmonary hypertension (PH) is an abnormal increase of the pressure inside the lung circulation. This condition can be caused by many different diseases. If PH persists for a long period of time, irreversible damage to the lung circulation and to the heart may ensue. A definitive diagnosis of PH req...
What is the current status of trial NCT06240871?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2013-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT06240871?
The interventions under investigation include: Pulmonary artery pressure measurements (OTHER).
Who is sponsoring clinical trial NCT06240871?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia